BillionToOne
BLLN
89.92
-0.28
-0.31%
BillionToOne
US · BLLN
#2109 by market cap
Listed 2025
89.92
-0.28
-0.31%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
Recent news
-
Rating change
CCORF Initiates BillionToOne(BLLN.US) With Buy Rating, Announces Target Price $120Market Newswire · 2026/9/2
-
Rating change
Guggenheim Maintains BillionToOne(BLLN.US) With Buy Rating, Raises Target Price to $125Market Newswire · 2026/6/29
-
Rating change
Analysts Offer Insights on Healthcare Companies: TruBridge (TBRG) and BillionToOne, Inc. Class A (BLLN)TipRanks · 2026/4/13
-
Rating change
J.P. Morgan Maintains BillionToOne(BLLN.US) With Buy Rating, Raises Target Price to $145Market Newswire · 2026/7/22
-
Rating change
Analysts Offer Insights on NA Companies: BillionToOne, Inc. Class A (BLLN) and MBX Biosciences, Inc. (MBX)TipRanks · 2026/8/7
-
Guggenheim Maintains BillionToOne(BLLN.US) With Buy Rating, Raises Target Price to $128Market Newswire · 2026/10/1
-
Piper Sandler Maintains BillionToOne(BLLN.US) With Buy Rating, Cuts Target Price to $130Market Newswire · 2026/11/10
-
Rating change
Analysts Have Conflicting Sentiments on These Healthcare Companies: BillionToOne, Inc. Class A (BLLN) and Bio-Techne (TECH)TipRanks · 2026/5/7
-
J.P. Morgan Maintains BillionToOne(BLLN.US) With Buy Rating, Cuts Target Price to $135Market Newswire · 2026/11/5
-
Rating change
Analysts Are Bullish on These NA Stocks: BillionToOne, Inc. Class A (BLLN), Carlsmed, Inc. (CARL)TipRanks · 2026/8/6
-
A Quick Look at Today's Ratings for BillionToOne(BLLN.US), With a Forecast Between $120 to $145Market Newswire · 2026/11/6
-
Rating change
Analysts Offer Insights on Healthcare Companies: BillionToOne, Inc. Class A (BLLN), ACADIA Pharmaceuticals (ACAD) and Revolution Medicines (RVMD)TipRanks · 2026/5/7
-
Rating change
J.P. Morgan Maintains BillionToOne(BLLN.US) With Buy Rating, Maintains Target Price $120Market Newswire · 2026/4/13
-
Rating change
BTIG Maintains BillionToOne(BLLN.US) With Buy Rating, Raises Target Price to $142Market Newswire · 2026/7/23
-
Rating change
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY), BillionToOne, Inc. Class A (BLLN) and Solventum Corporation (SOLV)TipRanks · 2026/5/25
-
Rating change
William Blair Initiates BillionToOne(BLLN.US) With Buy RatingMarket Newswire · 2026/8/7
-
Rating change
A Quick Look at Today's Ratings for BillionToOne(BLLN.US), With a Forecast Between $100 to $145Market Newswire · 2026/5/7
-
Rating change
Guggenheim Maintains BillionToOne(BLLN.US) With Buy Rating, Raises Target Price to $120Market Newswire · 2026/5/13
-
Piper Sandler Maintains BillionToOne(BLLN.US) With Buy Rating, Raises Target Price to $140Market Newswire · 2026/11/5
-
Rating change
Stifel Nicolaus Keeps Their Buy Rating on BillionToOne, Inc. Class A (BLLN)TipRanks · 2026/5/7
-
Form 144 | BillionToOne(BLLN.US) Officer Proposes to Sell 3.87 Million in Common StocksMarket Newswire · 2026/9/18
-
BillionToOne(BLLN.US) Officer Sells US$3.87 Million in Common StockMarket Newswire · 2026/9/22
-
BillionToOne(BLLN.US) Officer Sells US$3.03 Million in Common StockMarket Newswire · 2026/9/17
-
Rating change
Piper Sandler Maintains BillionToOne(BLLN.US) With Buy Rating, Cuts Target Price to $130Market Newswire · 2026/5/7
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:01:12 · For reference only, not investment advice and not tailored to your situation.
BillionToOne discussion 0 comments